Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2004

View Archived Issues

Bavarian Nordic highlights Imvamune progress

Polyvalent vaccine reported to improve survival in advanced melanoma

Novel fructose 1,6-bisphosphatase inhibitor lowers blood glucose in vivo

GPC Biotech achieves significant progress in anticancer drug programs during first quarter

Treatment options for restless legs syndrome

Dopamine D4 receptor agonist ABT-724 may offer safe and effective treatment of erectile dysfunction

NCX-911 may benefit ED patients with dysfunctional endogenous NO production

Enzon strengthens pipeline during Q3 through Onco TCS addition

Clinical efficacy of a BAY-43-9006 combination regimen in advanced melanoma

Vasogen updates Celacade phase III program

Disappointing preliminary phase IIa results for NGD-2000-1 in RA

FDA approves Rapinex powder for oral suspension 20 mg

Sepracor resubmits Estorra NDA

OSI and Genentech sign new Tarceva agreements

Second phase III trial of phenserine for Alzheimer's disease

Emisphere initiates new trial to select oral form of unfractionated heparin

Efaproxyn and Revaproxyn, new trade names for efaproxiral

New phase III hemodialysis trial for ferumoxytol iron replacement therapy

Phase II trial of Xcytrin for recurrent low-grade NHL under way

Labopharm to apply polymeric nanodelivery systems technology to cancer drug

Noven and Shire to proceed with further development of MethyPatch

Insegia chosen as trade name for G17DT

FDA accepts for filing Surfaxin NDA

Analgesic efficacy of HCT-3012 in osteoarthritis of the knee

Novel ecstasy analogues may be promising antiparkinsonian agents

Febuxostat reported to reduce serum urate levels of gout patients

Four series of delta opioid ligands prepared by AstraZeneca scientists

Antiangiogenic HARP-derived peptides newly developed at CNRS

New indole-based androgenic agents covered by Akzo Nobel patent

New macrolides able to potentiate the activity of antifungal azoles

Takeda claims novel neurotrophic factor production enhancers

New CDK inhibitors in early development at Banyu

Non-antibacterial macrolides with potential as antiiflammatory agents

Novel IL-8 receptor antagonists and their use described by GSK